In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analysts Optimistic On Aurobindo After Strong Earnings

Executive Summary

Analysts are enthusiastic about the US earnings prospects of leading Indian generic firm Aurobindo after the company reported a nearly 20% jump in consolidated net profit for the third quarter, and declared it would focus on digesting its acquisitions.

You may also be interested in...



Aurobindo Receives Warning Letter After Form 483

The US Food and Drug Administration has issued Aurobindo with a warning letter for an API site, shortly after one of its formulations plants received yet another Form 483, with ten observations.

Aurobindo In Trouble Again With FDA, Gets Form 483 With 11 Observations

The US Food and Drug Administration has flagged more problems at Aurobindo, issuing another Form 483 to the company over one of its plants in southern India. This one, containing 11 observations, sharply faults quality controls.

Autonomous Sandoz Set To Be Tighter And Leaner

With an optimized manufacturing base, a narrower geographic footprint, and a tighter portfolio focus on differentiated biosimilars and hard-to-make generics, Novartis believes a more autonomous Sandoz division can remain an “integral part” of the Swiss group.

Related Content

Topics

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel